多替阿巴拉米片在中国买的到吗?
Approved for marketing by the U.S. FDA in 2014, this is a treatment plan with DTG, an integrase inhibitor, as the core drug, coupled with two backbone drugs, abacavir and lamivudine, and made into a single-tablet treatment for promotion, making the core drug a great progress in HAART treatment.
There are four main advantages of Dolutegra Abalami Tablets: 1. Excellent efficacy and significant viral suppression effect; 2. The three drugs are equivalent, and both newly-treated and previously treated patients have high drug resistance barriers, which is not easy to lead to drug resistance; 3. It is easy to take, only needs to be taken once a day, and there is no need to consider food effects; 4. The drug has low side effects and good tolerability, and the discontinuation rate due to drug side effects is low; 5. The metabolic pathway has few interactions with other drugs.
Therefore, many domestic patients will also ask, can Docetabalamid tablets be purchased in China?
On January 22, 2018, the British multinational pharmaceutical company GlaxoSmithKline (GSK) announced that ViiV Healthcare, a joint venture of GSK, has officially launched the innovative AIDS treatment drug Dolutea Paramid Tablets in the Chinese market. Domestic patients can buy it in some hospitals in China with a doctor's prescription.
The use of Dolutegra Abalamid Tablets is also very simple. For adults and adolescents (weight not less than 40kg), the recommended dosage of Dolutegra Abalamid Tablets is one tablet each time, once a day. Adults or adolescents whose body weight is less than 40 kg should not be given dolutea as dolutea is a fixed-dose tablet and cannot be reduced.
Dolutegravir is a fixed-dose tablet and should not be used in patients requiring dose adjustments. If discontinuation or dose adjustment of one of the active ingredients is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these circumstances, physicians should refer to the respective product information for these medicines.
The listing in China has greatly facilitated the purchase of medicines by domestic patients. If you have any other questions, you can also consult the medical companion service.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)